logo
Ginkgo biloba is popular and provides many potential health benefits. What is it?

Ginkgo biloba is popular and provides many potential health benefits. What is it?

USA Today15-04-2025

Ginkgo biloba is popular and provides many potential health benefits. What is it?
Show Caption
Hide Caption
Omega-3 supplements: Do they really work?
You can find Omega-3s in fatty fish and plant-based sources like walnuts.
Many of today's most popular Western supplements, medicines and practices can trace their roots back to ancient Eastern medicine. These include practices aimed at tapping into a life force known as Qi (pronounced chee), which include acupuncture, massage therapy, tai chi, cupping, sound therapy and yoga.
Herbal medicine also has many of its roots in the East, including green tea, ginseng, ginger, goji berries and turmeric. Another of today's most popular herbal remedies and supplements is ginkgo biloba.
Here's what ginkgo biloba is, what benefits are associated with it and why it's not recommended to be taken by everyone.
What is ginkgo biloba?
Ginkgo biloba is a tree that's also known as the maidenhair tree—a botanical species that's grown in China for thousands of years. Because it's the only surviving member of an ancient plant family, maidenhair trees are often referred to as living fossils.
Though people throughout China and other East Asian countries sometimes consume ginkgo biloba seeds and leaves or use them in cooking, the form of the tree that most people consume in Western society comes from an extract of the tree's leaves — which is usually just referred to as ginkgo.
Ginkgo supplements are available in many forms, including pill, powder and liquid tinctures. "Dried ginkgo leaves can also be used to make tea," explains Dr. Uma Naidoo, director of nutritional and lifestyle psychiatry at Massachusetts General Hospital and the Harvard-trained nutritional psychiatrist behind "Calm Your Mind with Food."
Did you read? Green tea is known for its health benefits, but did you know this?
What are the benefits of ginkgo biloba?
Ginkgo extract and supplement are associated with many studied health benefits, Naidoo explains, such as helping slow the progression of age-related diseases, improving blood flow in those with coronary artery disease and reducing symptoms related to depression.
Such benefits are most commonly associated with ginkgo's high concentration of a type of antioxidant known as flavonoids — which are known to neutralize damage related to free radicals. "This is why ginkgo can help protect your heart and blood vessels from oxidative damage," says Josh Redd, a Johns Hopkins-trained doctor of naturopathic medicine and the author of "The Truth About Low Thyroid." This benefit can be especially useful for those with peripheral artery disease and hypertension, "but the improved circulation benefits can also be helpful to other people," he says.
Ginkgo also has properties that can help fight inflammation throughout the body, "which is crucial to combat as we age," Redd says. He adds that there is also compelling research showing that ginkgo "has genuine promise for cognitive health," including a 20-year population study demonstrating that consistent ginkgo use may slow cognitive decline over time.
Health benefits of ginger: A guide to the plant's powers
Is taking ginkgo biloba safe?
At the same time, some research on ginkgo is mixed and some of the data that shows promising benefits come from small studies or related to markers tracked in animal cells. Because of this, Naidoo says that larger-scale human studies are needed to more fully understand ginkgo's potential benefits.
What's more, ginkgo isn't for everyone. "Ginkgo has the potential to interact with medications like blood thinners, antidepressants and NSAIDS," says Naidoo. "While ginkgo's anticoagulant properties can help improve circulation, if you take blood-thinning medication medications, its blood-thinning effect can be dangerous," echoes Redd.
Even in individuals not taking such medications, Naidoo says some people experience side effects when taking high levels of ginkgo or when taking it over extended periods of time. Such side effects can include digestive issues, headache, allergic skin reactions and dizziness.
It's also important to note that supplements are not regulated by the U.S. Food and Drug Administration the way food and drugs are. "There are so many garbage supplements on the market, so quality matters tremendously," says Redd. "I recommend you avoid cheap mass-market supplement s... and to instead look for practitioner-brand nutraceuticals that undergo third-party testing for purity and quality."
For those concerned with taking ginkgo supplements, echoes Naidoo, "trying the tea variety of ginkgo may be the better way to start adding it to your diet."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jeremy Walston, Johns Hopkins Human Aging Project founder, dies
Jeremy Walston, Johns Hopkins Human Aging Project founder, dies

Yahoo

time3 hours ago

  • Yahoo

Jeremy Walston, Johns Hopkins Human Aging Project founder, dies

Dr. Jeremy Walston, who founded the Johns Hopkins Human Aging Project, died of glioblastoma June 10 at Gilchrist Center Baltimore. The Bolton Hill resident was 64. Born in Bowling Green, Ohio, he was the son of Gene Walston, a farmer, and Genevieve Walston, a homemaker who later worked for Verizon. Dr. Walston earned degrees at Capital University and the University of Cincinnati before moving to Baltimore and doing a general internal medicine residency at the Johns Hopkins Bayview Medical Center and a fellowship in Geriatric Medicine and Gerontology, also at Hopkins. Dr. Theodore DeWeese, dean of the Hopkins School of Medicine, said, 'Jeremy represented what it is to be a great Johns Hopkins faculty member. He brought the best care to patients in a kind and humane way.' 'He was a tremendous mentor and team builder. He brought nurses, public health professionals and engineers together,' said Dr. Cynthia M. Boyd, director of the Hopkins Geriatric Medicine and Gerontology division. 'He was also an exceptional scientist, a pioneer in the field of aging, biology and the field of frailty and resilience.' Dr. Walston met his partner and future husband, George Lavdas, at a party in 1982 at the Lawyer's Club at the University of Michigan Law School. 'His passion for the elderly began at a young age — at age 20,' Mr. Lavdas said. 'He was kind and caring. Jeremy also had a love of preserving nature, birds and the environment.' His sister, Wendy Walston Vaughn, said, 'Jeremy loved his family and friends. You could tell by how kind and generous he was. He was always reaching out to people to see how they were doing.' A Sun article, published in 2022, explained that the project he founded brought together a group of experts at at Bayview to better understand what causes age-related problems, with the goal of slowing or even fixing them. 'We're not aiming for people to live forever,' said Dr. Walston. 'But if we can slow the progression of disease and decline, that 10 to 20 years people live with disability, we can give them a better quality of life. We'll probably increase longevity as well.' The Sun's article said Dr. Walston conceived of the idea while treating his senior patients with cancer, heart disease, Alzheimer's disease and other conditions that develop over time. He wanted to improve their daily lives, and investigate the biological underpinnings of aging to improve later therapies or prevention strategies. Grace Ann Kubofcik, Howard County government civic watchdog, dies Eugene 'Gene' Clark, chief of staff for Maryland legislator, dies Thomas Nicholas Marudas, Baltimore harbor urban planner, dies Iris Reeves, former Baltimore City councilmember, dies Donald Warren Richardson, Richardson Farms co-owner, dies When the project launched, Dr. Walston described it as a 'big umbrella' of expertise from areas that include medical care, research, artificial intelligence and technology, engineering and business. Dr. Walston said he wanted equity and diversity to be an 'important element' of the aging project. A funeral will be held at 11 a.m. June 20 at St. Paul Lutheran Church, 14545 New Rochester Road in Pemberville, Ohio. A memorial service in Baltimore is being planned. Survivors include his husband and partner for more than 43 years, George Lavdas; two sons, Oliver Walston-Lavdas, of Baltimore and Alexander 'Alex' Walston-Lavdas, of Cocoa, Florida; a sister, Wendy Walston Vaughn, of Pemberville, Ohio; a step-mother, Ellen Walston, of Pemberville; two step-brothers, Brent Sandberg, of Perrysburg, Ohio and Justin Sandberg, of Pemberville. Have a news tip? Contact Jacques Kelly at and 410-332-6570.

Notification of Data Security Incident
Notification of Data Security Incident

Yahoo

time12 hours ago

  • Yahoo

Notification of Data Security Incident

LAS VEGAS, June 13, 2025 /PRNewswire/ -- Effortless Office Enterprises, LLC ("Effortless Office") has learned of a data security incident that may have involved personal and/or protected health information of certain employees and patients of Nevada Heart and Vascular ("NHV"). Notice of this incident has been sent to certain affected current/former employees, patients, and/or associated parties and provided resources to assist them. Upon learning of suspicious activity temporarily within its computer network, Effortless Office promptly took steps to secure the environment and began an investigation to determine the nature and scope of the issue. In addition, they began working to restore impacted systems as quickly as possible and engaged digital forensics specialists to conduct an investigation. The investigation determined that unauthorized access occurred at certain times between May 9, 2024 and July 23, 2024. After determining that personal information may have been impacted, Effortless Office completed a comprehensive programmatic and manual review to identify what personal information was impacted and to whom it belonged. On May 12, 2025, Nevada Heart & Vascular Center, LLP learned that certain personal information was impacted in connection with the incident. The following information may have been affected as a result of the incident: Social Security number, taxpayer identification number, driver's license or state identification, passport number, date of birth, account number, routing number, security code, payment card number, payment card pin, payment card expiration date, health insurance information, medical information, and biometric data. On June 13, 2025, a notification letter was mailed to affected individuals, for whom address information was available. A toll-free call center has been established to answer questions about the incident and address related concerns. Call center representatives are available Monday through Friday from 9:00 am to 9:00 pm Eastern Time and can be reached at 1-855-200-7910. The privacy and protection of personal and protected health information is a top priority for Effortless Office, which deeply regrets any inconvenience or concern this incident may cause. View original content: SOURCE Effortless Office Enterprises, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

Yahoo

time20 hours ago

  • Yahoo

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store